Vanguard reports 3.53M shares (5.53%) in Protagonist
Protagonist Therapeutics Inc Schedule 13G filing reports that Vanguard Portfolio Management beneficially owned 3,533,015 shares of Common Stock, representing 5.53% of the class as of 03/31/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Protagonist Therapeutics Inc Schedule 13G filing reports that Vanguard Portfolio Management beneficially owned 3,533,015 shares of Common Stock, representing 5.53% of the class as of 03/31/2026. The filer states sole dispositive power over the 3,533,015 shares and sole voting power for 51,804 shares. The filing is signed on 04/29/2026 by a Vanguard official.
Insights
Vanguard holds a >5% passive stake in Protagonist as of 03/31/2026.
Vanguard Portfolio Management reports beneficial ownership of 3,533,015 shares (5.53%), indicating it is a large institutional holder under Schedule 13G reporting rules. The filing lists 51,804 shares with sole voting power and 3,533,015 shares with sole dispositive power.
As a Schedule 13G disclosure, this typically reflects passive investment intent. Future Form 13D/13G amendments could change characterization; subsequent filings will show any active acquisition or disposition activity.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficially owned financial
Sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does filing a Schedule 13G mean for PTGX ownership?
When was the Schedule 13G for PTGX signed and filed?
Does the filing identify other persons with >5% interest in PTGX?
AI-generated analysis. How Rhea-AI works. Not financial advice.